Protocol Ledger

NCT05788289 · Phase II · TERMINATED

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Interventional Phase II clinical trial protocol NCT05788289 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-14 Enrollment: 4 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05788289
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05788289
Protocol FieldVerified Registry Value
NCT IdentifierNCT05788289
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment4 participants (ACTUAL)
Registered Start Date2023-03-14
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05788289
Hospital Research SiteLocationSite Profile
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI